Search

everythinglearnresearchcommunity

for

Search:↓

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Suppressing certain hormones might help prevent prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Certain genetic variants increase the risk of aggressive prostate cancer.

Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early balding at 40 increases prostate cancer risk.

TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

% free PSA and urinary markers help better identify prostate cancer.